You are here

Small India drugmakers struggle to meet US rules

They are under pressure to consider branching out to new, less-profitable markets or sell out to larger rivals

BT_20150630_LEPHARMA30_1746960.jpg
Indian producers say they have spent millions in high-end testing equipment, improved training and have hired larger teams in quality control since Ranbaxy was fined for manipulating clinical data.

Mumbai

INDIA'S smaller generic drugmakers, struggling to cope with a bruised reputation and tougher regulation in the United States, are under pressure to consider branching out to new, less-profitable markets or sell out to larger rivals.

Two years after its most high-profile